Apollo Therapeutics’ $15 million bet on Avalo’s anti-IL-18 monoclonal antibody appears to have paid off after the candidate aced a phase 2 trial in atopic dermatitis (AD). The phase 2a study involved ...
JPMorgan upgraded Apollo Commercial (ARI) to Overweight from Neutral with a price target of $10.50, up from $10. The firm believes the company has made progress resolving its “troubled” loans and is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback